Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer

centered over various methods of androgen signaling blockade. In this clinical setting, then it is important to understand how androgens and ADT affect the tumor uptake of new-generation imaging agents. ADT typically decreases the uptake of metabolic tracers such as FDG, radiolabeled choline, and fluciclovine, whereas the effect on the expression of transmembrane proteins such as PSMA is more complex and may depend on the tumor biology and the time of imaging after the start of ADT. Additional prospective studies are needed to understand this dynamic behavior and how it may be leveraged optimally for imaging and for radioligand therapy.